IS7714A - Lyfjasamsetningar úr módafíníl - Google Patents

Lyfjasamsetningar úr módafíníl

Info

Publication number
IS7714A
IS7714A IS7714A IS7714A IS7714A IS 7714 A IS7714 A IS 7714A IS 7714 A IS7714 A IS 7714A IS 7714 A IS7714 A IS 7714A IS 7714 A IS7714 A IS 7714A
Authority
IS
Iceland
Prior art keywords
modafinil
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
IS7714A
Other languages
English (en)
Other versions
IS2871B (is
Inventor
Heacock Craig
Parikh Alpa
Patel Piyush
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32511269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7714(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of IS7714A publication Critical patent/IS7714A/is
Publication of IS2871B publication Critical patent/IS2871B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS7714A 2002-09-13 2005-02-24 Töflur sem innihalda 250 til 450 mg af módafíníli IS2871B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41039502P 2002-09-13 2002-09-13
US10/660,058 US20040116532A1 (en) 2002-09-13 2003-09-11 Pharmaceutical formulations of modafinil
PCT/US2003/028651 WO2004024134A1 (en) 2002-09-13 2003-09-12 Pharmaceutical formulations of modafinil

Publications (2)

Publication Number Publication Date
IS7714A true IS7714A (is) 2005-02-24
IS2871B IS2871B (is) 2014-03-15

Family

ID=32511269

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7714A IS2871B (is) 2002-09-13 2005-02-24 Töflur sem innihalda 250 til 450 mg af módafíníli

Country Status (21)

Country Link
US (4) US20040116532A1 (is)
EP (1) EP1539126B1 (is)
JP (1) JP5039246B2 (is)
KR (1) KR101125462B1 (is)
CN (1) CN100528151C (is)
AU (1) AU2003267156B2 (is)
BR (1) BR0314514A (is)
CA (1) CA2498260C (is)
DK (1) DK1539126T3 (is)
EA (1) EA012964B1 (is)
ES (1) ES2392580T3 (is)
IL (1) IL167054A (is)
IS (1) IS2871B (is)
MX (1) MXPA05002827A (is)
NO (1) NO333614B1 (is)
NZ (1) NZ538941A (is)
PL (1) PL375833A1 (is)
PT (1) PT1539126E (is)
SI (1) SI1539126T1 (is)
TW (1) TWI335217B (is)
WO (1) WO2004024134A1 (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524359A (en) 2000-07-27 2005-06-24 Teva Pharma Crystalline and pure modafinil, and process of preparing the same
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
ES2487415T3 (es) * 2003-03-17 2014-08-20 Neurohealing Pharmaceuticals, Inc. Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
UA94380C2 (ru) * 2003-09-18 2011-05-10 Сефалон, Інк. Фармацевтические композиции модафинила с модифицированным высвобождением
US8153159B2 (en) 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
WO2005102342A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
BRPI0500520A (pt) * 2005-02-16 2006-09-26 Henry Jun Suzuki uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007093624A2 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) * 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
FR2987265B1 (fr) * 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) * 1923-11-20 1926-01-26 William A Cook Spring-forming die
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
DE2927988A1 (de) * 1979-07-11 1981-02-05 Thomae Gmbh Dr K Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel
US4431645A (en) * 1982-03-08 1984-02-14 Schering Corporation Antihypertensive agents
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4584285A (en) * 1983-06-02 1986-04-22 Schering Corporation Antihypertensive agents
US4710519A (en) * 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
US5084277A (en) * 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
TW272942B (is) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (is) * 1993-06-22 1995-09-08 Lafon Labor
FR2707637B1 (fr) * 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
ATE254463T1 (de) * 1996-01-19 2003-12-15 Glaxo Group Ltd Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd p−クロロ−N−(2−モルホリノエチル)ベンズアミドを含有する錠剤
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
AU718350B2 (en) * 1996-11-15 2000-04-13 Ajinomoto Co., Inc. Tablet composition
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
US6599529B1 (en) 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
PL356899A1 (en) 1998-12-18 2004-07-12 Abbott Laboratories Controlled release formulation of divalproex sodium
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
CN1249932A (zh) * 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) * 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
KR100911952B1 (ko) 2000-10-11 2009-08-13 세파론, 인코포레이티드 모다피닐 화합물을 포함하는 조성물
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
ATE417608T1 (de) * 2000-10-11 2009-01-15 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
IL158959A (en) 2001-05-25 2010-06-30 Cephalon Inc Solid pharmaceutical formulations comprising modafinil
US7576133B2 (en) * 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
MY137846A (en) 2002-07-08 2009-03-31 Ranbaxy Lab Ltd Processes for the preparation of oral dosage formulations of modafinil
US20080044468A1 (en) 2002-07-25 2008-02-21 Romi Barat Singh Processes For The Preparation Of Oral Dosage Formulations Of Modafinil
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Also Published As

Publication number Publication date
NO333614B1 (no) 2013-07-22
KR20050113163A (ko) 2005-12-01
CA2498260C (en) 2014-02-04
IS2871B (is) 2014-03-15
EP1539126A1 (en) 2005-06-15
CA2498260A1 (en) 2004-03-25
SI1539126T1 (sl) 2012-11-30
DK1539126T3 (da) 2012-11-19
NO20051079L (no) 2005-03-23
US8859621B2 (en) 2014-10-14
KR101125462B1 (ko) 2012-03-28
US20040116532A1 (en) 2004-06-17
AU2003267156B2 (en) 2010-03-11
ES2392580T3 (es) 2012-12-12
TWI335217B (en) 2011-01-01
WO2004024134A8 (en) 2005-07-21
JP5039246B2 (ja) 2012-10-03
US20080207761A1 (en) 2008-08-28
US20120316244A1 (en) 2012-12-13
CN100528151C (zh) 2009-08-19
PT1539126E (pt) 2012-11-14
TW200412934A (en) 2004-08-01
EP1539126B1 (en) 2012-08-29
HK1076734A1 (en) 2006-01-27
EA012964B1 (ru) 2010-02-26
JP2006522006A (ja) 2006-09-28
EA200500488A1 (ru) 2005-12-29
IL167054A (en) 2011-07-31
AU2003267156A1 (en) 2004-04-30
US20120322880A1 (en) 2012-12-20
PL375833A1 (en) 2005-12-12
MXPA05002827A (es) 2005-08-16
US8268892B2 (en) 2012-09-18
NZ538941A (en) 2007-09-28
US8686047B2 (en) 2014-04-01
BR0314514A (pt) 2005-08-09
WO2004024134A1 (en) 2004-03-25
CN1681486A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
IS7714A (is) Lyfjasamsetningar úr módafíníl
PT1501534E (pt) Formulacoes farmaceuticas
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
NO20033556L (no) Farmasöytiske formuleringer
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
KR20050009999A (ko) 약제학적 제제
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
NO20033384L (no) Farmasoytisk formulering
NO20033785D0 (no) Farmasöytisk formulering
EP1425019A4 (en) PHARMACEUTICAL COMPOSITION
IS8327A (is) Módafíníl breyttar losaðar lyfjasamsetningar
PT1513514E (pt) Formulações tópicas de hidroximatairesinol
NO20044916L (no) Preparater av sulfinylacetamid
EE200300589A (et) Ravimkoostised
ATE309789T1 (de) Darreichungsform von ibuprofen-natrium
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
ITMI20021684A1 (it) Composizione farmaceutica di peptide nasale
BRPI0312413A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
GB0202900D0 (en) Novel formulations of drugs
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
NO20043576L (no) Pharmaceutical formulation comprising melatonin
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
ATE409460T1 (de) Formulierung zur rektalen verabreichung thrombolytischer wirkstoffe
DE60323088D1 (de) Leberschützende wirkung der 10-o-p-hydroxybenzoylaucubin